^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AlphaLiquid® Detect

    Company:
    IMBdx
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    1year
    Personalized circulating tumor DNA assay precisely predicts the response of neoadjuvant chemotherapy in breast cancer patients (SABCS 2023)
    In addition, ctDNA at curative surgery also can predict NAC response in EBC patients. Long term ctDNA follow up of MRD would be warranted.
    Clinical • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive
    |
    AlphaLiquid® Detect